MOUNTAIN VIEW, Calif. (AP) ¿ Drugmaker Vivus Inc. says it plans to report results from two late-stage studies of its obesity drug candidate Qnexa Wednesday morning. The company said it will post the results from the EQUIP and CONQUER studies at 6 a.m., with a conference call to discuss the data at 8 a.m. Vivus reported two successful midstage trials in June, saying Qnexa helped type 2 diabetes patients lower their blood sugar levels and lose weight. Vivus shares rose 52 cents, or 8.1 percent in Tuesday regular trading, finishing at $6.91. In the aftermarket session, the stock jumped $1.34, or 19.4 percent, to $8.25.
More from Stocks
Boeing Apologizes Over Release of Test Pilot's Texts About 737 MAX
Ex-pilot had reportedly said the aircraft's MCAS system was 'running rampant.'
Tesla Reports Earnings on Wednesday: 3 Key Things to Watch For
The keys to Tesla's earnings report are all drivers of the company's ability to become consistently profitable.
Zuckerberg Set to Defend Libra on Capitol Hill Next Week. Here's What to Expect
While the hearing is focused on Facebook's Libra project, the congressional grilling could also extend to Facebook's acquisitions, antitrust concerns and posture on free speech.